Germany's Fresenius raises 2026 core EPS growth guidance
Germany's Fresenius raises 2026 core EPS growth guidance
Overview
Germany healthcare group's Q2 organic revenue rose 6% yr/yr to €5.86 bln
Core EPS for Q2 rose 14% in constant currency to €0.83
Company raised 2026 core EPS growth guidance to 10%-15% citing strong operational performance
Outlook
Fresenius raises 2026 core EPS guidance to 10%-15% constant-currency growth
Company expects 2026 group organic revenue growth of 4%-7%
Company notes ongoing macroeconomic and geopolitical volatility increasing operational uncertainty
Result Drivers
CORE BUSINESS PERFORMANCE - Co said strong operational performance at Fresenius Kabi and Fresenius Helios supported earnings development
NET INTEREST INCOME - Improved net interest income contributed to earnings growth
Company press release: ID:nEQ8Kgb1Ra
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue |
| EUR 5.86 bln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Fresenius SE & Co KGaA is €54.00, about 21.7% above its August 4 closing price of €44.36
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago
Reuters Recommended Reads
Aug 4 - Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again
Aug 4 - Bayer CEO says company now in a better position to make strategic choices
Aug 4 - BioNTech lowers 2026 sales outlook as COVID vaccine demand softens
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Fresenius SE & Co. KGaA
See all newsFresenius lifts 2026 expectations after strong Q3 (updated)
Healthcare firm Fresenius Q3 revenue rises on Kabi growth; lifts outlook
Brief: Fresenius Sees FY26 EBIT Margin Above 11.5%
Brief: Fresenius SE Q3 Revenue EUR 5,803 Million
Fresenius signs biosimilars pipeline agreement with WuXi Biologics (updated)